New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
13:25 EDTANAC, ANAC, ANAC, VRX, VRX, VRXDeutsche Bank's specialty pharma analyst to hold a conference call
Specialty Pharmaceuticals Analyst Steinberg, along with Principal Investigator Max Weisfeld, D.P.M. Hamilton Foot Care Clinic Mid Atlantic Research Center for Health, discuss current and emerging treatments for onychomycosis (nail fungus) with a focus on Valeant's IDP-108 (NDA filed with the FDA) and Anacor's tavaborole (Phase 3) on an Analyst/Industry conference call to be held on February 8 at 2 pm.
News For ANAC;VRX From The Last 14 Days
Check below for free stories on ANAC;VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 21, 2014
11:22 EDTVRXAllergan CEO: At the end of the day, it's up to Valeant to say what's going on
Subscribe for More Information
09:10 EDTVRXOn The Fly: Pre-market Movers
HIGHER: Allergan (AGN), up 0.5% after Q2 results, FY14 outlook beat expectations and the company announces plans to reduce workforce by about 1,500 employees as part of restructuring. Also, Valeant (VRX) announced it has contacted both the SEC and Canadian financial authorities regarding Allergan's "apparent attempt to mislead investors and manipulate the market for Valeant common shares by continuing to make false and misleading statements regarding Valeant's business"... Extreme Networks (EXTR), up 13% after raising Q4 EPS, revenue view... Gas Natural (EGAS), up 6% after confirming it rejected $13 per share unsolicited offer from Algonquin Power... EMC (EMC), up 4.5% after the WSJ says Elliot Management took a stake of over $1B in the firm and plans to push the company to break itself up... GoPro, (GPRO), up 2.8% after initiated at several firms including Citigroup, Barclays and JPMorgan... Kandi Technologies (KNDI), up 6% after China Daily said China will not to waive a sales tax on electric cars made by foreign companies. Tesla (TSLA) is down 1% following the report. UP AFTER EARNINGS: Halliburton (HAL), up 0.5%... LOWER: Reynolds American (RAI), down 2.3% after a Florida jury hit the company with $23.6B in punitive damages in a lawsuit filed by the widow of a longtime smoker. Shares of fellow tobacco companies also fell after the jury decision, as Lorillard (LO) fell 2% and Altria (MO) slid 1.6%... Yum! Brands (YUM), down 2% after AP reported that a Shanghai TV station said a food supplier sold expired beef and chicken to the company's KFC brand in China along with to McDonald's (MCD), which is down 0.7%. DOWN AFTER EARNINGS: PetMed Express (PETS), down 2.4%... Hasbro (HAS), down 1.3%.
07:15 EDTVRXValeant Allergan contacts Quebec, U.S. regulators regarding Allergan statements
Valeant (VRX) has contacted both the Autorite des marches financiers in Quebec and the SEC regarding Allergan (AGN) apparent attempt to "mislead investors and manipulate the market for Valeant common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information." The latest statements were made last Friday when Allergan asserted in an SEC filing that Bausch + Lomb's pharmaceutical sales were stagnant or declining. Valeant's decision to contact the authorities also reflects concerns raised by several Canadian Valeant shareholders about comments made about Valeant by Allergan's management during recent meetings with these investors in Canada.
07:09 EDTVRXValeant, Ackman go to SEC over Allergan claims, CNBC reports
Subscribe for More Information
07:03 EDTANACAnacor, Sandoz enter into agreement for commercialization of Kerydin in the U.S.
Anacor Pharmaceuticals (ANAC) announced that it has entered into an exclusive agreement with Sandoz, a Novartis (NVS) company, pursuant to which Sandoz will distribute and commercialize Anacorís drug KERYDIN topical solution, 5% in the United States. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN. On July 8, Anacor announced that the U.S. FDA approved the New Drug Application for KERYDIN, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today. The agreement with Sandoz entitles Anacor to upfront payments totaling $40M and an additional milestone payment of $25M expected to be paid in January 2015. Under the agreement, Sandoz and Anacor will share equally, under a long-term profit-sharing arrangement, the gross profits accrued by Sandoz on sales of KERYDIN, except that in 2015 Anacor will start receiving profit-sharing payments after the first $50M of gross profits have been accrued by Sandoz. The long-term profit-sharing arrangement includes cumulative minimum profit-sharing payments to Anacor in 2016 totaling $45M. Anacor will also have the option to repurchase all rights in KERYDIN from Sandoz on the later of three years from launch or December 31, 2017, at a price to be determined pursuant to the agreement. Under the terms of the agreement, Anacor will supply product to Sandoz at cost through Anacorís contract manufacturers, and Sandoz will be responsible for all of its selling, marketing, distribution, general and administrative costs related to the commercialization of KERYDIN. Anacor will hold the NDA and will be responsible for any further development of KERYDIN.
06:34 EDTVRXCapital Research sells nearly all its Allergan stake, WSJ reports
Subscribe for More Information
July 18, 2014
12:51 EDTVRXKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
11:27 EDTVRXSamlyn undecided on support for Valeant bid for Allergan, Dow says
Subscribe for More Information
July 17, 2014
16:45 EDTVRXPershing Square looks to obtain consents for special meeting
Subscribe for More Information
08:08 EDTVRXValeant receives FDA clearance for Victus Femtosecond Laser Platform
Subscribe for More Information
07:00 EDTVRXPaulson says Allergan could be wroth $220 per share, WSJ reports
Subscribe for More Information
July 16, 2014
17:46 EDTVRXAckman says he thinks Allergan-Valeant deal eventually gets done
Subscribe for More Information
17:42 EDTVRXPershing Square's Ackman says Allergan's attack on Valeant unprecedented
Subscribe for More Information
10:36 EDTVRXTreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:16 EDTVRXPershing Square sends letter to Allergan's board of directors
Pershing Square Capital Management announced it has sent a letter to Allergan's Board of Directors. Pershing Square last Friday filed definitive solicitation materials with the U.S. SEC to seek shareholder support for a special meeting of Allergan shareholders and is now actively soliciting shareholder support to call the meeting. At this special meeting, Allergan shareholders will be able to voice their opinions on a number of critical matters, including the proposed removal of six incumbent members of the Allergan board, the proposed appointment of an independent slate of directors and certain other proposed provisions to improve Allerganís corporate governance.
08:16 EDTVRXLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTVRXTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 14, 2014
12:47 EDTVRXAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
08:13 EDTVRXAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:02 EDTVRXValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use